Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
Chinese University of Hong Kong · Guangdong General Hospital · +14 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
3,306
total citations
- FWCI
- 184.04
- Percentile
- 100%
- References
- 34
Citations per year
Authors
258Topics & keywords
Topics
Keywords
- Medicine
- Pembrolizumab
- Internal medicine
- Lung cancer
- Oncology
- Chemotherapy
- Performance status
- Progression-free survival
No related works found for this paper.